Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. - Hidalgo,M.; Siu,L.L.; Nemunaitis,J. (J Clin Oncol, 2001)